JOURNAL OF BIOLOGICAL CHEMISTRY, v.289, no.38, pp.26618 - 26629
Abstract
Background: PPARβ ligands can be used in numerous metabolic syndromes. Results: A novel non-agonist PPARβ ligand, UHC1 exhibited great beneficial effects on glucose metabolism and anti-inflammatory response. Conclusion: UHC1 shows anti-diabetic action by blocking CDK5-mediated PPARβ phosphorylation. Significance: UHC1 can be a novel therapeutic agent for use in type 2 diabetes and related metabolic disorders.